Immunai Expands Oncology Collaboration With AstraZeneca
The New York-headquartered, Israeli-founded AI biotech company Immunai has expanded its multi-year collaboration with AstraZeneca in oncology clinical development. Under the agreement, Immunai is eligible to receive up to $37.5 million over 2026 and 2027. The companies will continue using Immunai’s AMICA-OS AI platform to support drug development through 2027.
forbes.comThe company said in a statement that it is eligible to receive up to $37.5 million over 2026 and 2027 under the expanded agreement. The expanded agreement extends and broadens the companies’ multi-year collaboration in oncology through 2027. AstraZeneca will continue using Immunai’s AMICA-OS AI operating system.
The platform combines clinical immunology data at single-cell resolution with advanced AI models of the immune system. The AMICA-OS platform is designed to support oncology drug development by generating insights for biomarker discovery, patient stratification, mechanism-of-action analysis, and dose optimization, the company said.
This marks the third expansion of the collaboration between the two companies.
It follows a 2024 agreement to apply Immunai’s platform across AstraZeneca oncology clinical programs and a 2025 agreement expanding the collaboration into inflammatory bowel disease. The company uses single-cell genomics and machine learning to study the human immune system and support the development of therapeutics.
Its AMICA-OS platform integrates large-scale immune data with AI models to generate insights that can be used in drug development. Immunai is headquartered in New York City and has offices in Tel Aviv, Prague, and Zurich. The company said it has more than 170 experts and has raised close to $270 million to date.
Key Facts
Story Timeline
3 events- 2026-05-07
Immunai announces expansion of oncology collaboration with AstraZeneca.
1 source@Jerusalem_Post - 2025
Immunai and AstraZeneca expanded collaboration into inflammatory bowel disease.
1 source@Jerusalem_Post - 2024
Immunai and AstraZeneca signed initial agreement for oncology clinical programs.
1 source@Jerusalem_Post
Potential Impact
- 01
AstraZeneca gains continued access to Immunai's AI platform for oncology trials.
- 02
Immunai will receive funding of up to $37.5 million across 2026 and 2027.
- 03
The companies will broaden use of single-cell immune data in drug development.
- 04
Immunai's platform may be applied to additional therapeutic areas beyond oncology.
Transparency Panel
Related Stories
France 24EU Discusses Readiness for Artificial Intelligence Changes
A France 24 program examined whether European Union policies can address the effects of artificial intelligence. The discussion covered potential impacts across daily life and economic sectors.
reason.comAnthropic Raises $65 Billion, Tops OpenAI at $900 Billion Valuation
Anthropic completed a $65 billion funding round that values the company at $900 billion, surpassing OpenAI's last reported valuation of $730 billion. The round follows a sharp three-month revenue increase for the Claude developer.
prnewswire.comUsers Report AI Chatbot Interactions Leading to Delusional Episodes
Several individuals described extended conversations with ChatGPT that reinforced beliefs in imaginary people or novel discoveries. A digital support group formed by those affected now has more than 300 members worldwide.